Author
EF. Domino
Dr.Antonio Esteve Foundation
TORRE ESTEVEPasseig de la Zona Franca, 109
08038 Barcelona
Tel:
93 433 53 20
E-mail:
fundacion@esteve.org
The third volume of Pharmacology Revisited: an Esteve Foundation Series gathers 33 articles related to psychopharmacology. In Selected publications shaping psychopharmacology as a discipline, professor Edward F. Domino, from the Department of Pharmacology of the University of Michigan, compiled the most relevant texts in this field published in journals like The Lancet, Pharmacology & Toxicology or The Medical Journal of Australia. As is usual in this Esteve Foundation’s series, a facsimile edition of these articles is provided.
Full document | ||
Full PDF | EF. Domino | [wpdm type=”btn3″] |
Chapters | ||
Acknowledgements | [wpdm id=23 type=”btn”] | |
Introduction | EF. Domino | [wpdm id=21 type=”btn”] |
Reference list | [wpdm id=22 type=”btn”] | |
Index | [wpdm id=20 type=”btn”] | |
1. Un nouveau stabilisateur végétatif (LE 4560 RP) | H. Laborit / P. Huguenard / R. Allaume | [wpdm type=”btn3″] |
2. Utilisation en thérapeutique psychiatrique d\’une phénothiazine d\’action centrale élective (4560 RP) | J. Delay / P. Deniker / JM. Harl | [wpdm type=”btn3″] |
3. Propriétés pharmacodynamiques du chlorhydrate de chloro-3 (diméthylamino-3\’ propyl)-10 phénothiazine (4.560 R.P.) | S. Courvoisier / J. Fournel / R. Ducrot / M. Kolsky / P. Koetschet | [wpdm type=”btn3″] |
4. A controlled clinical test of a new psycholeptic drug (haloperidol) | E. Brandrup / P. Kristjansen | [wpdm type=”btn3″] |
5. The butyrophenone story | PAJ. Janssen | [wpdm type=”btn3″] |
6. Antipsychotic drug doses and neuroleptic/dopamine receptors | P. Seeman / T. Lee / M. Chau-Wong / K. Wong | [wpdm type=”btn3″] |
7. The current status of the dopamine hypothesis of schizophrenia | A. Carlsson | [wpdm type=”btn3″] |
8. Comments and reply on \”The current status of the dopamine hypothesis of schizophrenia\” | DF. Klein / AJ. Friedhoff / HY. Meltzer / SH. Snyder / A. Carlsson | [wpdm type=”btn3″] |
9. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine | J. Kane / G. Honigfeld / J. Singer / H. Meltzer / Clozaril Collaborative Study Group | [wpdm type=”btn3″] |
10. Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia | HY. Meltzer | [wpdm type=”btn3″] |
11. Iproniazid (Marsilid®) phosphate, a therapeutic agent for mental disorders and debilitating diseases | GE. Crane | [wpdm type=”btn3″] |
12. The treatment of depressive states with G 22355 (imipramine hydrochloride) | R. Kuhn | [wpdm type=”btn3″] |
13. A concept for a role of serotonin and norepinephrine as chemical mediators in the brain | BB. Brodie / PA. Shore | [wpdm type=”btn3″] |
14. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect | IP. Lapin / GF. Oxenkrug | [wpdm type=”btn3″] |
15. Initial clinical trial based on biochemical methodology of zimelidine (a serotonin uptake inhibitor) in depressed patients | B. Siwers / VA. Ringberger / JR. Tuck / F. Sjöqvist | [wpdm type=”btn3″] |
16. A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy)-N-ethyl-3-phenylpropylamine | DT. Wong / FP. Bymaster / JS. Horng / BB. Molloy | [wpdm type=”btn3″] |
17. The psychosedative properties of methaminodiazepoxide | LO. Randall / GAH. Schallek / EF. Keith / RE. Bagdon | [wpdm type=”btn3″] |
18. Tolerance development with chlordiazepoxide in relation to the plasma levels of the parent compound and its main metabolites in mice | JD. Christensen | [wpdm type=”btn3″] |
19. Selective antagonists of benzodiazepines | W. Hunkeler / H. Möhler / L. Pieri / P. Polc / EP. Bonetti / R. Cumin / R. Schaffner / W. Haefely | [wpdm type=”btn3″] |
20. New concepts on the mechanism of action of benzodiazepines | E. Costa / A. Guidotti / CC. Mao / A. Suria | [wpdm type=”btn3″] |
21. Lithium salts in the treatment of psychotic excitement | JFJ. Cade | [wpdm type=”btn3″] |
22. The treatment of manic psychoses by the administration of lithium salts | M. Schou / N. Juel-Nielsen / E. Strömgren / H. Voldby | [wpdm type=”btn3″] |
23. Lithium as a prophylactic agent: Its effect against recurrent depressions and manic-depressive psychosis | PC. Baastrup / M. Schou | [wpdm type=”btn3″] |
24. N-allyl-norcodeine and N-allyl-normorphine, two antagonists to morphine | ER. Hart | [wpdm type=”btn3″] |
25. A medical treatment for diacetylmorphine (heroin) addiction: A clinical trial with methadone hydrochloride | VP. Dole / M. Nyswander | [wpdm type=”btn3″] |
26. Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain | A. Goldstein / LI. Lowney / BK. Pal | [wpdm type=”btn3″] |
27. Opiate receptor: Demonstration in nervous tissue | CB. Pert / SH. Snyder | [wpdm type=”btn3″] |
28. Identification of two related pentapeptides from the brain with potent opiate agonist activity | J. Hughes / TW. Smith / HW. Kosterlitz / LA. Fothergill / BA. Morgan / HR. Morris | [wpdm type=”btn3″] |
29. Determination and characterization of a cannabinoid receptor in rat brain | WA. Devane / FA. Dysarz III / M. Ross Johnson / LS. Melvin / AC. Howlett | [wpdm type=”btn3″] |
30. Psychotomimetic drugs: Chemical and pharmacological aspects | A. Hofmann | [wpdm type=”btn3″] |
31. Study of a new schizophrenomimetic drug – Sernyl | ED. Luby / BD. Cohen / G. Rosenbaum / JS. Gottlieb / R. Kelley | [wpdm type=”btn3″] |
32. Pharmacologic effects of CI-581, a new dissociative anesthetic, in man | EF. Domino / P. Chodoff / G. Corssen | [wpdm type=”btn3″] |
33. Dynamics of drug dependence: Implications of a conditioning theory for research and treatment | A. Wikler | [wpdm type=”btn3″] |
34. Self-administration of psychoactive substances by the monkey: A measure of psychological dependence | G. Deneau / T. Yanagita / MH. Seevers | [wpdm type=”btn3″] |